Relief Therapeutics Holding AG (RLF) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.115x

Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) has a cash flow conversion efficiency ratio of -0.115x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-3.76 Million ≈ $-4.75 Million USD) by net assets (CHF32.63 Million ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RLF days of operational coverage to measure how many days the company can operate on defensive assets alone.

Relief Therapeutics Holding AG - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Relief Therapeutics Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Relief Therapeutics Holding AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Relief Therapeutics Holding AG ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ostim Endustriyel Yatirimlar ve Isletme AS IS:OSTIM	-0.011x
TAEYANG Corporation KQ:053620	0.035x
Eternal Energy Public Company Limited BK:EE	-0.078x
BioRem Inc. V:BRM	-0.074x
Imago Mulia Persada Tbk PT JK:LFLO	0.093x
First Graphene Ltd F:M11	-0.111x
Aeries Technology Inc. NASDAQ:AERT	-0.778x
White Cliff Minerals Ltd AU:WCN	-0.510x

Annual Cash Flow Conversion Efficiency for Relief Therapeutics Holding AG (2006–2024)

The table below shows the annual cash flow conversion efficiency of Relief Therapeutics Holding AG from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see RLF market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF36.66 Million ≈ $46.35 Million	CHF-2.92 Million ≈ $-3.69 Million	-0.080x	+76.41%
2023-12-31	CHF52.23 Million ≈ $66.03 Million	CHF-17.61 Million ≈ $-22.27 Million	-0.337x	-103.40%
2022-12-31	CHF145.42 Million ≈ $183.85 Million	CHF-24.11 Million ≈ $-30.48 Million	-0.166x	+15.73%
2021-12-31	CHF181.53 Million ≈ $229.50 Million	CHF-35.71 Million ≈ $-45.15 Million	-0.197x	+27.67%
2020-12-31	CHF67.04 Million ≈ $84.76 Million	CHF-18.23 Million ≈ $-23.05 Million	-0.272x	-419.88%
2019-12-31	CHF14.30 Million ≈ $18.08 Million	CHF-748.00K ≈ $-945.67K	-0.052x	-80.17%
2018-12-31	CHF21.28 Million ≈ $26.91 Million	CHF-618.00K ≈ $-781.32K	-0.029x	+48.15%
2017-12-31	CHF20.95 Million ≈ $26.48 Million	CHF-1.17 Million ≈ $-1.48 Million	-0.056x	+56.88%
2016-12-31	CHF22.24 Million ≈ $28.11 Million	CHF-2.89 Million ≈ $-3.65 Million	-0.130x	+65.57%
2015-12-31	CHF17.66 Million ≈ $22.32 Million	CHF-6.66 Million ≈ $-8.42 Million	-0.377x	-13.81%
2014-12-31	CHF26.35 Million ≈ $33.31 Million	CHF-8.73 Million ≈ $-11.04 Million	-0.331x	+22.01%
2013-12-31	CHF20.61 Million ≈ $26.06 Million	CHF-8.76 Million ≈ $-11.08 Million	-0.425x	-124.58%
2012-12-31	CHF-2.69 Million ≈ $-3.40 Million	CHF-4.65 Million ≈ $-5.87 Million	1.729x	+107.83%
2011-12-31	CHF464.04K ≈ $586.67K	CHF-10.24 Million ≈ $-12.95 Million	-22.075x	-6931.42%
2010-12-31	CHF52.38 Million ≈ $66.22 Million	CHF-16.44 Million ≈ $-20.79 Million	-0.314x	-437.12%
2009-12-31	CHF56.73 Million ≈ $71.73 Million	CHF-3.32 Million ≈ $-4.19 Million	-0.058x	+57.83%
2008-12-31	CHF68.94 Million ≈ $87.15 Million	CHF-9.55 Million ≈ $-12.08 Million	-0.139x	-139.60%
2007-12-31	CHF64.50 Million ≈ $81.54 Million	CHF-3.73 Million ≈ $-4.72 Million	-0.058x	-267.47%
2006-12-31	CHF66.13 Million ≈ $83.61 Million	CHF2.28 Million ≈ $2.89 Million	0.035x	--

About Relief Therapeutics Holding AG

SW:RLF Switzerland Biotechnology

Market Cap

$45.93 Million

CHF36.33 Million CHF

Market Cap Rank

#23136 Global

#203 in Switzerland

Share Price

CHF2.89

Change (1 day)

+0.87%

52-Week Range

CHF2.12 - CHF3.66

All Time High

CHF280.00